• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sanofi-Aventis

Actelion, J&J re-enter takeover negotations

December 21, 2016 By Sarah Faulkner

Actelion, J&J re-enter takeover negotations

Actelion (VTX:ATLN) and Johnson & Johnson (NYSE:JNJ) have re-entered talks to reach a takeover deal, after the US healthcare giant reportedly abandoned its efforts last week. Some suggest that this could mean the end of Sanofi‘s (NYSE:SNY) attempt to make a deal with the Swiss biotech firm, according to Reuters.  J&J and Actelion had been engaged in informal talks […]

Filed Under: Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

Actelion gains on Sanofi deal rumors

December 16, 2016 By Sarah Faulkner

Actelion gains on Sanofi deal rumors

Actelion (VTX:ATLN) shares jumped more than 8% to 214 Swiss francs after reports that Sanofi (NYSE:SNY) and the Swiss biotech are nearing a takeover deal that would value Actelion at $29.6 billion. After Johnson & Johnson (NYSE:JNJ) abandoned its efforts to reach an agreement with Actelion this week, Sanofi stepped in to pursue negotiations. Sanofi is expected to offer […]

Filed Under: Featured, Mergers & Acquisitions, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

Lilly, Boehringer’s Basaglar long-acting insulin now available in the U.S.

December 15, 2016 By Sarah Faulkner

Lilly, Boehringer's Basaglar long-acting insulin now available in the U.S.

Eli Lilly (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals said today that its insulin glargine injection, Basaglar, is available by prescription in the U.S. Basaglar is a long-acting insulin with the same amino acid sequence as Sanofi‘s (NYSE:SNY) Lantus. The companies also offer resources for patients beginning insulin treatment, including an app for smartphones and tablets which provides […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Boehringer Ingelheim Pharmaceuticals, Eli Lilly & Co., Sanofi-Aventis

Eli Lilly, Express Scripts offer insulin discount program

December 14, 2016 By Sarah Faulkner

Eli Lilly

Eli Lilly (NYSE:LLY) said it is teaming up with pharmacy benefit manager Express Scripts (NSDQ:ESRX) to offer discounts on the US pharma giant’s insulin products for uninsured patients and people with high-deductible insurance plans. The program will begin January 1, 2017 and will cover Lilly’s insulins Humalog, Humulin, and the biologic Basaglar. Lilly said it anticipates the program […]

Filed Under: Diabetes, Featured, Wall Street Beat Tagged With: CVS Health, Eli Lilly & Co., Express Scripts, Novo Nordisk, Sanofi-Aventis

Actelion, Sanofi in talks after J&J backs out of negotiations

December 14, 2016 By Sarah Faulkner

Actelion, J&J re-enter takeover negotations

Actelion (VTX:ATLN) and Sanofi (NYSE:SNY) are reportedly in talks to reach a takeover deal after Johnson & Johnson (NYSE:JNJ) said yesterday that it has closed negotiations with the Swiss biotech. J&J and Actelion have been in informal talks for nearly 2 months and the US company has made an offer valued at 250 Swiss francs per share. J&J said yesterday […]

Filed Under: Featured, Mergers & Acquisitions, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

CMS pinpoints cost-driving drugs in newly released data

December 9, 2016 By Sarah Faulkner

CMS

Centers for Medicare & Medicaid Services released 5 years of pricing data for a list of more than 5,000 drugs this week. The data illustrate that a handful of cost-driving drugs experienced price hikes in 2015, which cost taxpayers millions in added Medicare spending. The price of some drugs went up almost 500%, with name-brand […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS), Mylan, Sanofi-Aventis

Sanofi throws hat in the ring with J&J’s in Actelion pursuit

December 6, 2016 By Sarah Faulkner

Sanofi logo

Sanofi (NYSE:SNY) is reportedly considering a bid for Actelion Pharmaceuticals (VTX:ATLN), competing with an offer made to the Swiss biotech by Johnson & Johnson (NYSE:JNJ). Bloomberg reported that Sanofi is working with advisers to assess its options and has made its interest known informally to Actelion. The French drugmaker has not made a formal comment on the matter […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Novartis, Pfizer Inc., Roche, Sanofi-Aventis

J&J approaches Actelion

November 28, 2016 By Sarah Faulkner

Actelion, Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is reportedly in preliminary discussions to buy Actelion Pharmaceuticals (VTX:ATLN) in a deal estimated to be as high as $247 (250 Swiss francs) per share, although the European biotech said there is no guarantee the deal will go through. J&J’s CEO Alex Gorsky said this year that the company is interested in deals […]

Filed Under: Featured, Mergers & Acquisitions, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Novartis, Roche, Sanofi-Aventis

Novo Nordisk, Sanofi win FDA nods for diabetes drugs

November 22, 2016 By Sarah Faulkner

Sanofi sues Nordisk over Tresiba marketing claims in U.S.

Both Novo Nordisk (NYSE:NVO) and Sanofi (NYSE:SNY) said yesterday that they won FDA approval for pre-filled pens with drug combinations indicated for adults with Type II diabetes. Paris-based Sanofi’s Soliqua 100/33 is an injectable medicine composed of 2 diabetes drugs – insulin glargine and lixisenatide. The drug is approved for adults with Type II diabetes not controlled with less than […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: Novo Nordisk, Sanofi-Aventis

Novo Nordisk shares dive after long-term growth cut

October 28, 2016 By Sarah Faulkner

Novo Nordisk

(Reuters) — Top insulin maker Novo Nordisk (NYSE:NVO) slashed its long-term profit growth forecast today, signaling no let-up in its struggles to crack the U.S. market to which its chief executive said its commitment would not waver. The Danish firm’s shares fell by as much as 19% to a 30-month low, wiping more than $15 billion off […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: Eli Lilly & Co., Novo Nordisk, Sanofi-Aventis

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS